The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Abstract
Purpose: To develop and validate a risk score for relapse in the CNS in patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: A total of 2,164 patients (18 to 80 years old) with aggressive B-cell lymphomas (80% DLBCL) treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera International Trial, were analyzed for occurrence of relapse/progression in the CNS. The resulting risk model was validated in an independent data set of 1,597 patients with DLBCL identified in the British Columbia Cancer Agency Lymphoid Cancer database. Results: The risk model consists of the International Prognostic Index (IPI) factors in addition to involvement of kidneys and/or adrenal glands (CNS-IPI). In a three-risk group model, the low-risk group (46% of all patients analyzed), the intermediate-risk group (41%), and the high-risk group (12%) showed 2-year rates of CNS disease of 0.6% (CI, 0% to 1.2%), 3.4% (CI, 2.2% to 4.4%), and 10.2% (CI, 6.3% to 14.1%), respectively. Patients from the validation British Columbia Cancer Agency data set showed similar rates of CNS disease for low-risk (0.8%; CI, 0.0% to 1.6%), intermediate-risk (3.9%; CI, 2.3% to 5.5%), and high-risk (12.0%; CI, 7.9% to 16.1%) groups. Conclusion: The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Close to 90% of patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk < 5%; they may be spared any diagnostic and therapeutic intervention. In contrast, those in the high-risk group have a > 10% risk of CNS relapse and should be considered for CNS-directed investigations and prophylactic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Self-citationPfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70002-0 · Cited by 1,130
Self-citationJohnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Self-citationTilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P. W., Pfreundschuh, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv304 · Cited by 930
Self-citationModelling Survival Data in Medical Research
Collett, D. (2015) · Chapman & Hall/CRC eBooks · doi:10.1201/b18041 · Cited by 759
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Petrich, A. M., Gandhi, M., Jovanovic, B., Castillo, J. J., Rajguru, S., Yang, D. T., Shah, K. A., Whyman, J. D., Lansigan, F., Hernandez-Ilizaliturri, F. J., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578963 · Cited by 467
Récher, C., Coiffier, B., Haioun, C., Molina, T. J., Fermé, C., Casasnovas, O., Thiéblemont, C., Bosly, A., Laurent, G., Morschhauser, F., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61040-4 · Cited by 355
Cited by
Sehn, L. H., & Salles, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027612 · Cited by 1,175
Self-citationRecommendations for the management of hemophagocytic lymphohistiocytosis in adults
La Rosée, P., Horne, A., Hines, M., von Bahr Greenwood, T., Machowicz, R., Berliner, N., Birndt, S., Gil-Herrera, J., Girschikofsky, M., Jordan, M. B., et al. (2019) · Blood · doi:10.1182/blood.2018894618 · Cited by 1,108
The association between an anxiety disorder and cancer in medical history
Zeynalova, N., Schimpf, S., Setter, C., Yahiaoui-Doktor, M., Zeynalova, S., Lordick, F., Loeffler, M., & Hinz, A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.019 · Cited by 22
Self-citation
Metadata
- Authors
- Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., Glass, B., Scott, D. W., Gascoyne, R. D., Connors, J. M., Ziepert, M., Pfreundschuh, M., Loeffler, M., & Savage, K. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-09-10
- Volume
- 34
- Issue
- 26
- Pages
- 3150-3156
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2462981464
- Cited by
- 453
- References
- 18
- FWCI
- 22.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. https://app.cochat.ai/papers/10.1200/jco.2015.65.6520
- The paper
- Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., Glass, B., Scott, D. W., Gascoyne, R. D., Connors, J. M., Ziepert, M., Pfreundschuh, M., Loeffler, M., & Savage, K. J. (2016). CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.6520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.